Beren Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 103

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $300M

  • Investors
  • 18

Beren Therapeutics General Information

Description

Developer of cyclodextrin-based therapeutics designed to discover, develop, and deliver novel therapies for conditions characterized by defective cholesterol trafficking while integrating the needs of patients, caregivers, clinicians, and health systems throughout the development process. The company offers cholesterol-trafficking focused therapeutics, expanded access support programs, and patient access initiatives, enabling patients with rare cholesterol trafficking disorders and their caregivers to access treatments and receive long-term clinical and family support.

Contact Information

Website
www.berentx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2101 Corporate Center Drive
  • Newbury Park, Suite 100
  • Thousand Oaks, CA 91320
  • United States
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 2101 Corporate Center Drive
  • Newbury Park, Suite 100
  • Thousand Oaks, CA 91320
  • United States

Beren Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beren Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 10-Jun-2026 $300M Completed Clinical Trials - Phase 3
3. Seed Round 07-Feb-2023 Completed Clinical Trials - Phase 3
2. Seed Round 01-Aug-2021 $30M Completed Clinical Trials - Phase 3
1. Seed Round 10-Aug-2020 $30M $30M Completed Clinical Trials - Phase 3
To view Beren Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Beren Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cyclodextrin-based therapeutics designed to discover, develop, and deliver novel therapies for conditions c
Drug Discovery
Thousand Oaks, CA
103 As of 2026

Austin, TX
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beren Therapeutics Competitors (5)

One of Beren Therapeutics’s 5 competitors is IntraBio, a Formerly VC-backed company based in Austin, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
IntraBio Formerly VC-backed Austin, TX
Disc Medicine Formerly VC-backed Watertown, MA
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA
Argenx Formerly VC-backed Zwijnaarde, Belgium
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
You’re viewing 5 of 5 competitors. Get the full list »

Beren Therapeutics Patents

Beren Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026172287-A1 Cyclodextrin derivatives and uses thereof Pending 14-Feb-2025
WO-2026172290-A1 Cyclodextrin derivatives and uses thereof Pending 14-Feb-2025
WO-2026022777-A1 2-hydroxypropyl beta-cyclodextrins for use in a method of treating niemann-pick disease type c in subjects with infantile onset Pending 26-Jul-2024
WO-2026018209-A1 Modified cyclodextrin compounds and methods for their use Pending 19-Jul-2024
AU-2024323697-A1 Isomerically pure beta-cyclodextrin derivatives and uses thereof Pending 16-Aug-2023 C08B37/0012
To view Beren Therapeutics’s complete patent history, request access »

Beren Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beren Therapeutics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advection Growth Capital Merchant Banking Firm Minority
Athos Capital (Hong Kong) Hedge Fund Minority
Eisai Corporate Venture Capital Minority
Founders Fund Venture Capital Minority
Gaingels Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

Beren Therapeutics FAQs

  • When was Beren Therapeutics founded?

    Beren Therapeutics was founded in 2020.

  • Where is Beren Therapeutics headquartered?

    Beren Therapeutics is headquartered in Thousand Oaks, CA.

  • What is the size of Beren Therapeutics?

    Beren Therapeutics has 103 total employees.

  • What industry is Beren Therapeutics in?

    Beren Therapeutics’s primary industry is Drug Discovery.

  • Is Beren Therapeutics a private or public company?

    Beren Therapeutics is a Private company.

  • What is Beren Therapeutics’s current revenue?

    The current revenue for Beren Therapeutics is .

  • How much funding has Beren Therapeutics raised over time?

    Beren Therapeutics has raised $330M.

  • Who are Beren Therapeutics’s investors?

    Advection Growth Capital, Athos Capital (Hong Kong), Eisai, Founders Fund, and Gaingels are 5 of 18 investors who have invested in Beren Therapeutics.

  • Who are Beren Therapeutics’s competitors?

    IntraBio, Disc Medicine, Rhythm Pharmaceuticals, Argenx, and Apellis Pharmaceuticals are competitors of Beren Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process